Kornimate/medical-research-clean huggingface dataset:
chemotherapy combined with cik treating colon cancer

Conditions: Colorectal Cancer; Cytokine-induced Killer Cells; Postoperative Complications; Survival

Summary: cytokine-induced killer cells (cik) is an auxiliary antitumor treatment. the investigators aim to evaluate the clinical efficacy of chemotherapy combined with cik in the treatment of postoperative colorectal cancer patients. and to provide useful reference for the clinical application of cik in colorectal cancer patients.

over the past decade, advances in combination chemotherapy regimens for colorectal cancer have led to significant improvement in progression-free and overall survival. cytokine-induced killer cells (cik) is an auxiliary antitumor treatment. research has demonstrated the median overall survival (os) in patients received cik combined with chemotherapy (5-fluorouridine, leucovorin and oxaliplatin \[folfox4\] plan) was significantly increased compared with that in patients received chemotherapy alone. furthermore, there was a trend toward superior progression-free survival time (pfs) in patients received cik combined with chemotherapy compared with that in patients received chemotherapy alone. the investigators aim to evaluate the clinical efficacy of chemotherapy (folfox4) combined with cik in the treatment of postoperative colorectal cancer patients. and to provide useful reference for the clinical application of cik in colorectal cancer patients.

Eligibility criteria:
inclusion criteria: 1. tumor, nodes, metastasis (tnm) stage of ii or iii; 2. patients received radical resection of colon cancer; 3. pathological diagnosis of adenocarcinoma; 4. patients not received radiotherapy and chemotherapy before surgery; 5. the preoperative examination confirmed without systemic metastasis; 6. patient has the karnofsky score more than 70 points; 7. subjects signed informed consent. exclusion criteria: 1. patients who was serious allergy to any of the ingredients of drugs used in this study; 2. patients who unable to comply with the treatment plan or research program; 3. patients with severe systemic disease that the researchers judged will be unable to complete the study; 4. patients have severe heart disease, such as myocardial infarction within 6 months; 5. patients who have received chemotherapy or systemic antitumor therapy (such as monoclonal antibody therapy); 6. patients received radiotherapy; 7. having other malignant tumors in the last 5 years, but not including who has been cured through surgery and survived 5 year of disease-free; 8. any unstable systemic diseases (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction, serious arrhythmias, liver, kidney or metabolic diseases within six months). 9. patients who do not get effective treatment of inflammation, eye infections or predisposing factors; 10. physical examination or laboratory findings evidence reasonable doubt who is ill or use of related drugs could affect the study; 11. patients with serious active infections; 12. woman who are pregnant or lactating.
study of nicotine for the prevention of ponv

Conditions: Postoperative Nausea and Vomiting

Summary: the purpose of this study is to determine whether nicotine is effective in the prevention of nausea and vomiting in non-smokers undergoing surgery


Eligibility criteria:
inclusion criteria: * adults (18-80 years) * asa i-ii, non-smokers (or ex-smokers who have not been smoking for more than 2 years) * undergoing elective surgery (ent, abdominal, urological, gynaecological); and * consenting to take part in the study will be included. exclusion criteria: * smokers (cigarette, pipe, cigar) * patients undergoing nicotine replacement therapy * prolonged postoperative intubation * postoperative nasogastric tube

Keywords: nausea vomiting retching emesis surgery anesthesia
the significance of postoperative muscle wasting in pancreatic cancer

Conditions: Pancreatic Cancer

Summary: to assess the impact of preoperative sarcopenia and postoperative skeletal muscle wasting on the outcomes of patients with resectable pancreatic cancer who underwent pancreatectomy.

previous studies have revealed that sarcopenia, defined as generalized loss of skeletal muscle mass, is a poor prognostic factor following surgery. however, research focusing on postoperative muscle wasting and its influence on the prognosis of resectable pancreatic cancer (pc) is limited. investigators retrospectively reviewed 208 patients who underwent pancreatectomy for pc at the national cheng kung university hospital (nckuh) between june 2002 and april 2020. clinical information regarding patient characteristics, pathological parameters, and biochemical features was collected from all patients using electronic medical records (emrs) under an irb-approved protocol (b-er-110-420) at nckuh. preoperative psoas major area and the degree of muscle reduction at 3 months postoperatively were calculated using computed tomography to define sarcopenia and drastic muscle wasting. patients were assigned to two groups based on sarcopenia or drastic muscle wasting, and compared for postoperative morbidity, disease free survival (dfs), and overall survival (os).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pancreatic cancer * must be able to undergo pancreatectomy * must be able to undergo pre- and post-operative abdominal computed tomography scan exclusion criteria: * unresectable pancreatic cancer
trial comparing moviprep and phosphoral as bowel prep before colonoscopy

Conditions: Colorectal Cancer

Summary: using moviprep patients use shorter time to do a bowel prep before colonoscopy. no major single center has docuemted the advantage of using moviprep as bowel prep before colonoscopy.this randomised study was conducted to compare moviprep with the present standard: phosphoral to investigate the degree of bowel cleasing before colonoscopy in patients suspected of colorectal cancer, and to investigate number of days where patients need to stay home.


Eligibility criteria:
inclusion criteria: * patients suspected of colorectal cancer scheduled for colonoscopy exclusion criteria: * patients with previous colorectal surgery * colonis stenosis * asa \> 2

Keywords: bowel prep safety efficacy
this study will assess the etiology, potential risk factors, and seizure types in patients over 50 with epileptic seizure disorder, using laboratory tests, eeg, and neuroimaging findings.

Conditions: Epilepsy

Summary: this study underscores the importance of studying the etiology, clinical characteristics, and types of epilepsy in the elderly to improve diagnosis and management in our community.


Eligibility criteria:
inclusion criteria: * the diagnosis of epilepsy and epileptic seizures will be clinically established based on patient history, following the glossary of descriptive terminology for ictal semiology by the international league against epilepsy (ilae) task force on classification and terminology, as well as the operational classification of seizure types (ilae, 2017). exclusion criteria: * • inability to determine the onset of epilepsy or epileptic seizures, or a history of seizures occurring before the age of 50. * metabolic disturbances such as hypoglycemia, uremia, or electrolyte imbalances. * patients who refuse to participate in the study.

Keywords: epilepsy,elderly,seizure,eeg.
open versus closed reduction of mandibular sub-condylar fractures

Conditions: Mandibular Fractures

Summary: patients with mandibular sub-condylar fractures underwent either either open reduction with internal fixation (orif) or closed reduction with external fixation (cref) and were followed up for 6 months to assess treatment adequacy with the hypothesis that orif is superior to cref.


Eligibility criteria:
inclusion criteria: * age 16-60 years * displaced mandibular subcondylar fractures(mcfs) irrespective of multiple mandibular fractures. exclusion criteria: * bilateral mcfs * mcf with mid-facial fractures * insufficient bilateral dentition * medically unfit for surgery * old healed mandibular fractures * history of previous mandibular surgery for the same indication

Keywords: mandibular subcondylar fractures mouth opening open reduction and internal fixation closed reduction with external fixation
the efficiency of writing endoscopic reports by artificial intelligence and physicians: a randomized controlled trial

Conditions: Gastrointestinal Disease

Summary: the purpose of this study is to compare the efficiency of writing endoscopic reports by artificial intelligence and physicians through a randomized controlled trial.

digestive endoscopy permits early detection of gastrointestinal diseases and improving the patients' quality of life. however, writing endoscopic report takes a lot of manpower and time, reducing the efficiency of endoscopy. our center has developed a structured diagnostic report generation system for digestive endoscopy, which can generates the report by artificial intelligence. here, we compare the efficiency of writing endoscopic reports by artificial intelligence and physicians through a randomized controlled trial.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 80 years； * patients undergoing gastroscopy and colonoscopy examination with anesthesia； * patients able to give informed consent exclusion criteria: * patients with the contraindications to endoscopic examination; * a history of gastrointestinal cancers; * allergic to anaesthetics in previous medical history; * the endoscopic procedure cannot be completed due to stenosis, obstruction, solid food or complications of anaesthesia.

Keywords: endoscopic report artificial intelligence gastrointestinal disease writing efficiency
a study of the safety and immunogenicity of repeated rhc1inh administration

Conditions: Genetic Disorders; Hereditary Angioedema

Summary: hereditary angioedema ("hae") is a disease characterized by recurrent tissue swelling affecting various body locations. recent literature shows that patients with frequent attacks may benefit from long-term prophylaxis. this study aims to evaluate the safety and prophylactic effect of weekly administrations of 50 iu/kg recombinant c1 inhibitor ("rhc1inh").


Eligibility criteria:
inclusion criteria: * aged at least 18 years * signed informed consent * comfirmed diagnosis of hae with baseline plasma level of functional c1inh activity of less than 50% of normal, and/or proven hae ,mutation in c1inh gene. exclusion criteria: * a history of anaphylaxis or severe allergy (i.e. requiring medication) to food, proteins and/or drugs. * a history of allergic reactions to c1inh products or rabbit protein. * any reported sae related to study drug administration (withdrawal criterium) * elevated ige against rabbit dander (\>0.35 ku/l; immunocap assay; phadia) * a diagnosis of acquired c1inh deficiency. * woman of child bearing potential, pregnancy or breast-feeding * previous treatment within the last 3 months with plasma-derived c1inh * any clinically significant abnormality in the routine haematology, biochemistry and urinalysis * any condition or treatment that in the opinion of the investigator might interfere with the evaluation of the study objectives. * any changes since screening that would exclude subject based on above exclusion criteria.
positive peers intervention clinical trial

Conditions: HIV Infections

Summary: the goal of this clinical trial is to learn if the positive peers mobile app intervention increases rates of viral suppression in young (13-34 y/o) persons with hiv. does use of the positive peers app improve viral suppression among young minority persons with hiv? what user characteristics are associated with a) viral suppression, b) retention in care, and c) perceived hiv-related stigma? participants will: * download the mobile app onto their personal smartphone * use the mobile app as they find useful * complete online surveys at enrollment, 3 mo, 6, mo, 9 mo and 12 months.

participants will load the positive peers app on their personal device (either immediately or after a 6 month delay) and be encouraged to use the app regularly. eligible patients who decline participation in the intervention will be asked to participate in an observational arm. all participants will complete a brief baseline survey. participants in the immediate or delayed arms will also complete surveys at 3, 6, 9, and 12 months. medical data will be collected from the medical record and usage data will be collected from the app itself. medical data will be collected for 12 months prior to enrollment and 18 months after enrollment. at the end of the study, participants are welcome to continue to use the app.

Eligibility criteria:
inclusion criteria: * hiv+ * identifies as either a racial, ethnic, sexual or gender minority one of the following: * newly diagnosed within last 12 months * out of care (greater than 6 months between any two hiv provider visits in last 24 months) * not virally suppressed (any viral load \> 200 copies in last 24 months) * has a working smartphone * functional english ability exclusion criteria: * prior use of positive peers mobile app
is negativity of autoantibodies a marker of severity in auto-immune hepatitis?

Conditions: Auto-immune Hepatitis

Summary: evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). in case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched.

evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). in case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched. patients from the guadeloupean constitutive center of rare diseases (ccrd filfoie) and from the saint-antoine hospital will be retrospectively analyzed, and new patients will be prospectively followed.

Eligibility criteria:
inclusion criteria: * - any patient over 18 years old * patient followed at hôpital saint-antoine or treated for hai or in guadeloupe within the framework of the ccrd filfoie for an acute or chronic aih under immunosuppressive treatment * patient affiliate or beneficiary of a social security scheme * free, informed and written consent signed by the patient and the investigator o exclusion criteria: - patient under 18 years old * patient not able to give his/her consent * viral hepatitis: viruses a to e, epstein-barr virus, cytomegalovirus and herpes simplex virus * isolated primary biliary cholangitis * isolated primary sclerosing cholangitis * drug-induced liver injury * wilson disease * alcoholic hepatitis * hemochromatosis * sickle cell disease and heart liver * non-alcoholic steato-hepatitis

Keywords: autoantibodies auto-immune hepatitis prognosis afrocaribbean population
pharmacokinetics and metabolism of [14c] bms-986231 in healthy male participants

Conditions: Heart Decompensation, Acute

Summary: an intravenous infusion in healthy subjects to obtain information about the absorption, metabolism, and excretion (ame) of bms-986231


Eligibility criteria:
inclusion criteria: * signed informed consent * target population: healthy males with no clinically significant deviations from normal in medical history, physical examinations, vital signs, electrocardiograms (ecgs), physical measurements, and clinical laboratory tests * body weight between 75 and 95 kg, inclusive; body mass index (bmi) between 18 to 32 kg/m2. exclusion criteria: * history of chronic illness * chronic headaches * recurrent dizziness * personal or family history of heart disease * personal history of bleeding diathesis other protocol defined inclusion/exclusion criteria could apply
impact of catheter size on peri-operative pain after robotic assisted laparoscopic prostatectomy

Conditions: Prostate Cancer

Summary: this study is designed to assess the effect of catheter size on postoperative catheter pain, urinary continence, urinary flow rates, post void residuals, international prostate symptom scores (ipss), and quality of life (qol) score, as well as long term complications after robotic assisted laparoscopic prostatectomy.

subjects identified to receive a robotic assisted laparoscopic prostatectomy.were randomized to either a 16 french or 20 french catheter at the completion of the prostatectomy. all prostatectomies were performed by one of three surgeons at the investigator's institution. preoperative demographics and operative data were recorded for each group. catheters remained in place for 7-14 days. subjects were asked on postoperative day 7 to report their catheter-related pain and amount of opioid medication used. urinary symptoms and quality of life scores and pads per day were recorded at 6 weeks and 12 weeks post-operatively.

Eligibility criteria:
inclusion criteria: * identified as candidate for robotic assisted laparoscopic prostatectomy exclusion criteria: * having filled a prescription for opioid medication in last 2 months. * known latex allergy * known pre-operatively that catheter placement will exceed 14 days * history of pelvic radiation * significant deviation from normal operative protocol
a systematic review of factors associated with pulmonary arterial hypertension in systemic sclerosis

Conditions: Pulmonary Arterial Hypertension; Systemic Sclerosis

Summary: this protocol is of a systematic review for risk factors of pulmonary arterial hypertension in systemic sclerosis.

a systematic review was conducted to determine the risk/associated factors for pulmonary arterial hypertension in systemic sclerosis, including clinical/disease characteristics, antibody status, test results and biomarkers. the frequency of publications featuring a risk/association were reported. the following databases were searched: medline, embase, the cochrane library, web of science, and scopus. the following search terms were used: ( essential pulmonary hypertension or familial primary pulmonary hypertension or hypertension, pulmonary or hypertension,lung or hypertensive pulmonary vascular disease or idiopathic pulmonary arterial hypertension or lung arterial hypertension or lung artery hypertension or lung hypertension or primary pulmonary hypertension or pulmonary arterial hypertension or pulmonary artery hypertension or pulmonary fixed hypertension or pulmonary hypertensive disease or pulmonary hypertensive diseases or pulmonary hypertensive disorder or pulmonary hypertensive disorders ) and ( generalised scleroderma or generalized scleroderma or progressive scleroderma or progressive sclerodermia or progressive sclerosis,systemic or progressive systemic sclerosis or scleroderma, generalised or scleroderma, generalized or scleroderma, progressive or scleroderma, systemic or sclerosis,progressive systemic or sclerosis,systemic or sclerosis,systemic progressive or systemic progressive sclerosis or systemic scleroderma or systemic sclerosis,progressive or scleroderma, limited or limited scleroderma or limited cutaneous scleroderma or diffuse scleroderma or progressive diffuse scleroderma or scleroderma, diffuse ) and ( prevalence or prevalence study or relative risk or risk factors )

Eligibility criteria:
inclusion criteria: * studies were included they were (1) in patients with ssc; and if they (2) determined pah with right heart catheterization; (3) involved a comparison of ssc patients with and without pah; and (4) had sample size larger than 20. exclusion criteria: * studies were excluded if they were review articles, and if the study was written in languages other than english. when the same patients were used in more than one analysis, the most recent or largest sample-size study was included.

Keywords: systemic sclerosis scleroderma pulmonary hypertension pulmonary arterial hypertension
gut health enhancement by eating favourable food

Conditions: Microbial Colonization

Summary: within the geef om je buik study the effect of 8 weeks intervention with either a diet rich in fiber or fermented food on the gut microbiota will be investigated.

this study is a randomized controlled trial (rct) with three intervention groups (high dietary fiber group (hdf), high fermented foods group (hff), and a control group (cg)). the total duration of the study is 5 months and consists of an 8-week intervention ( 2-week ramp up period with dietary guidelines, followed by 6-week period with dietary guidelines + additional consumption of study products) and a follow-up after 3 months. in total 147 subjects will be included.

Eligibility criteria:
inclusion criteria: * men and women, aged ≥18 - ≤70 years; * being able to read and speak dutch; * willing to keep a stable dietary pattern throughout the study, apart from the dietary advice in the study; * having a smartphone compatible with the lifedata or pocketq app to fill out the daily questionnaires. exclusion criteria: * having a disease or medical condition which can influence the study results such as diabetes, cancer, diagnosed irritable bowel syndrome, renal disease, liver enzyme abnormality, malignant neoplasm, or a history of inflammatory diseases (such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease); * having a history of intestinal surgery that might interfere with study outcomes (this does not include an appendectomy or cholecystectomy); * average dietary fiber intake of ≥18 gram (women) or ≥22 gram (men) per day, according to the fiber screen questionnaire (see f1 questionnaires); * more than 3 servings of fermented foods per day as assessed with the fermented food frequency questionnaire (see f1 questionnaires); * having a body mass index (bmi) of ≥ 30 kg/m2 (self-reported); * currently following a strict diet and unwilling or unable to change; for example, a gluten free diet or a "crash diet" using meal substitutes; * specific food allergies that interfere with dietary intervention (for example, gluten, lactose, etc); * use of prebiotics, probiotics and/or synbiotics (this should be stopped 4 weeks before the start of the study) and use of fiber supplements; * use of antibiotic treatment less than 3 months before start of the study and/or use of antibiotics during the study; * use of medication that can interfere with the study outcomes, as judged by the medical supervisor; * alcoholic use of ≥14 (women) or ≥28 (men) glasses of alcoholic beverages per week; * use of soft or hard drugs (should be stopped at least 4 weeks before start of the study); * being pregnant or lactating; * participation in another clinical trial at the same time; * student or employee working at either food, health and consumer research from wageningen food and biobased research, microbiology at vu, the mlds, at wholefiber, keep food simple or at cidrani; * unable to follow or comply to study rules.

Keywords: fiber fermented food immune system microbiota